The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to ...

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...